Conclusions
NAFLD, PWH, fibrosis
HEPATIC STEATOSIS, FIBROSIS
This study provides preliminary evidence that add-on maraviroc as therapy for HIV-NAFLD may be safe, feasible and acceptable. Although there were differences in the trend for ALT and LSM scores, with improvement in the MVC+OBT versus OBT group, the 95% CI contained zero, which was consistent with there being no detectable differences, and the study was not powered to evaluate changes in these characteristics. Overall, these data support a larger RCT assessing efficacy of add-on maraviroc on hepatic steatosis and fibrosis in PWH and NAFLD.